通过瘤性PIK3CA重新激活多效应诱导乳腺瘤异质性
Alexandra Van Keymeulen1, May Yin Lee1, Marielle Ousset1
1Université Libre de Bruxelles, IRIBHM, Brussels B-1070, Belgium.
这项研究显示PIK3CA基因突变可以重新编程正常的乳腺细胞,从而导致多种瘤类型和乳腺癌异质性. 了解这种细胞起源是开发新治疗策略的关键.
科学领域:
- 癌症学
- 遗传学
- 细胞生物学
背景情况:
- 乳腺癌是一种异质性疾病,有多种不同的亚型.
- PIK3CA和TP53是乳腺癌中经常发生突变的基因.
- PIK3CA驱动的瘤异质性的细胞起源和机制尚未完全理解.
研究的目的:
- 使用基因小鼠模型定义PIK3CA突变乳腺瘤的细胞起源.
- 研究PIK3CA突变对瘤异质性和细胞命运的影响.
- 探索TP53与PIK3CA突变的作用.
主要方法:
- 在小鼠中使用质素 (K) 5-CreER ((T2) 和K8-CreER ((T2) 系统来表达致癌性Pik3ca ((H1047R) 的基因操纵.
- 瘤形成,细胞类型 (光线/基底) 和受体状态 (ER/PR) 的分析.
- 转录造型识别与细胞命运过渡相关的基因特征.
主要成果:
- 在基底细胞中的瘤性Pik3ca表达诱导了光线ER(+) PR(+) 瘤,而在光线细胞中的表达则导致光线或基底类瘤.
- 同时删除p53加速了瘤的发展,增加了瘤的攻击性.
- PIK3CA突变诱导了细胞命运转变,基底细胞变得类似于光细胞,而光细胞变得类似于基底细胞,从而导致瘤的进展.
结论:
- 已确定PIK3CA驱动的乳腺瘤的细胞起源.
- 瘤性PIK3CA在瘤开始的早期激活了血统受限细胞中的多能基因程序.
- 这些发现提供了关于乳腺癌异质性和潜在治疗点的见解.
更多相关视频
06:29Modeling Breast Cancer via an Intraductal Injection of Cre-expressing Adenovirus into the Mouse Mammary Gland
Published on: June 7, 2019
07:13Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer
Published on: March 26, 2014
相关概念视频
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Cancers Originate from Somatic Mutations in a Single Cell
Abnormal Proliferation
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
